Shenzhen Salubris Pharmaceuticals (002294.SZ) SAL0137 drug clinical trial application accepted

Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that the company has received an acceptance notice issued by the National Medical Products Administration for the clinical trial application of its innovative small molecule drug SAL0137 (project code: SAL0137) developed independently by the company. SAL0137 is an oral small molecule drug with proprietary intellectual property rights developed by the company. The application submitted this time is for the clinical trial of SAL0137 for the treatment of elevated lipoprotein (a).